Cargando…

TERT Core Promotor Mutations in Early-Onset Bladder Cancer

Activating mutations in the core promoter of the TERT gene have been described in many different tumor entities. In vitro models showed a two- to fourfold increase in transcriptional activity of the TERT promoter through creation of a consensus binding motif for Ets/TCF transcription factors caused...

Descripción completa

Detalles Bibliográficos
Autores principales: Giedl, Johannes, Rogler, Anja, Wild, Andreas, Riener, Marc-Oliver, Filbeck, Thomas, Burger, Maximilian, Rümmele, Petra, Hurst, Carolyn, Knowles, Margaret, Hartmann, Arndt, Zinnall, Ulrike, Stoehr, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910583/
https://www.ncbi.nlm.nih.gov/pubmed/27313781
http://dx.doi.org/10.7150/jca.15006
_version_ 1782438031822684160
author Giedl, Johannes
Rogler, Anja
Wild, Andreas
Riener, Marc-Oliver
Filbeck, Thomas
Burger, Maximilian
Rümmele, Petra
Hurst, Carolyn
Knowles, Margaret
Hartmann, Arndt
Zinnall, Ulrike
Stoehr, Robert
author_facet Giedl, Johannes
Rogler, Anja
Wild, Andreas
Riener, Marc-Oliver
Filbeck, Thomas
Burger, Maximilian
Rümmele, Petra
Hurst, Carolyn
Knowles, Margaret
Hartmann, Arndt
Zinnall, Ulrike
Stoehr, Robert
author_sort Giedl, Johannes
collection PubMed
description Activating mutations in the core promoter of the TERT gene have been described in many different tumor entities. In vitro models showed a two- to fourfold increase in transcriptional activity of the TERT promoter through creation of a consensus binding motif for Ets/TCF transcription factors caused by these mutations. TERT core promoter mutations are the most common mutations in bladder cancer with a frequency between 55.6% and 82.8% described so far, and are independent of stage and grade. Since limited data on molecular alterations of early-onset bladder tumors exists, we assessed the frequency of TERT core promoter mutations in early-onset bladder cancer. Two cohorts of bladder tumors (early-onset patient group; n=144 (age of onset of disease ≤45 years); unselected, consecutive group; n=125) were examined for TERT core promoter mutations. After microdissection and extraction of DNA the corresponding hotspot regions in the TERT core promoter were examined by Sanger-sequencing or a SNaPshot approach. A significantly lower frequency of TERT core promoter mutations was found in tumors from the early-onset cohort compared to the consecutive cohort (57.6% vs. 84.8%, p<0.001). Among the early-onset cohort cases younger than the cohort's median age of 39 years at disease onset showed a significantly reduced number of TERT promoter mutations (31/67, 46,3%) than cases aged between 39 and 45 years (52/77, 67.5%; p=0.012). This association was not found in the consecutive cases. Mutation status was independent of tumor stage and grade. We conclude that in tumors from early-onset bladder cancer patients TERT core promoter mutations are not as frequent as in bladder tumors from consecutive cases, but seem to play an important role there as well. In patients below 39 years of age TERT core promoter mutations are a more infrequent event, suggesting different mechanisms of tumorigenesis in these young patients.
format Online
Article
Text
id pubmed-4910583
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-49105832016-06-16 TERT Core Promotor Mutations in Early-Onset Bladder Cancer Giedl, Johannes Rogler, Anja Wild, Andreas Riener, Marc-Oliver Filbeck, Thomas Burger, Maximilian Rümmele, Petra Hurst, Carolyn Knowles, Margaret Hartmann, Arndt Zinnall, Ulrike Stoehr, Robert J Cancer Research Paper Activating mutations in the core promoter of the TERT gene have been described in many different tumor entities. In vitro models showed a two- to fourfold increase in transcriptional activity of the TERT promoter through creation of a consensus binding motif for Ets/TCF transcription factors caused by these mutations. TERT core promoter mutations are the most common mutations in bladder cancer with a frequency between 55.6% and 82.8% described so far, and are independent of stage and grade. Since limited data on molecular alterations of early-onset bladder tumors exists, we assessed the frequency of TERT core promoter mutations in early-onset bladder cancer. Two cohorts of bladder tumors (early-onset patient group; n=144 (age of onset of disease ≤45 years); unselected, consecutive group; n=125) were examined for TERT core promoter mutations. After microdissection and extraction of DNA the corresponding hotspot regions in the TERT core promoter were examined by Sanger-sequencing or a SNaPshot approach. A significantly lower frequency of TERT core promoter mutations was found in tumors from the early-onset cohort compared to the consecutive cohort (57.6% vs. 84.8%, p<0.001). Among the early-onset cohort cases younger than the cohort's median age of 39 years at disease onset showed a significantly reduced number of TERT promoter mutations (31/67, 46,3%) than cases aged between 39 and 45 years (52/77, 67.5%; p=0.012). This association was not found in the consecutive cases. Mutation status was independent of tumor stage and grade. We conclude that in tumors from early-onset bladder cancer patients TERT core promoter mutations are not as frequent as in bladder tumors from consecutive cases, but seem to play an important role there as well. In patients below 39 years of age TERT core promoter mutations are a more infrequent event, suggesting different mechanisms of tumorigenesis in these young patients. Ivyspring International Publisher 2016-05-07 /pmc/articles/PMC4910583/ /pubmed/27313781 http://dx.doi.org/10.7150/jca.15006 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Research Paper
Giedl, Johannes
Rogler, Anja
Wild, Andreas
Riener, Marc-Oliver
Filbeck, Thomas
Burger, Maximilian
Rümmele, Petra
Hurst, Carolyn
Knowles, Margaret
Hartmann, Arndt
Zinnall, Ulrike
Stoehr, Robert
TERT Core Promotor Mutations in Early-Onset Bladder Cancer
title TERT Core Promotor Mutations in Early-Onset Bladder Cancer
title_full TERT Core Promotor Mutations in Early-Onset Bladder Cancer
title_fullStr TERT Core Promotor Mutations in Early-Onset Bladder Cancer
title_full_unstemmed TERT Core Promotor Mutations in Early-Onset Bladder Cancer
title_short TERT Core Promotor Mutations in Early-Onset Bladder Cancer
title_sort tert core promotor mutations in early-onset bladder cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910583/
https://www.ncbi.nlm.nih.gov/pubmed/27313781
http://dx.doi.org/10.7150/jca.15006
work_keys_str_mv AT giedljohannes tertcorepromotormutationsinearlyonsetbladdercancer
AT rogleranja tertcorepromotormutationsinearlyonsetbladdercancer
AT wildandreas tertcorepromotormutationsinearlyonsetbladdercancer
AT rienermarcoliver tertcorepromotormutationsinearlyonsetbladdercancer
AT filbeckthomas tertcorepromotormutationsinearlyonsetbladdercancer
AT burgermaximilian tertcorepromotormutationsinearlyonsetbladdercancer
AT rummelepetra tertcorepromotormutationsinearlyonsetbladdercancer
AT hurstcarolyn tertcorepromotormutationsinearlyonsetbladdercancer
AT knowlesmargaret tertcorepromotormutationsinearlyonsetbladdercancer
AT hartmannarndt tertcorepromotormutationsinearlyonsetbladdercancer
AT zinnallulrike tertcorepromotormutationsinearlyonsetbladdercancer
AT stoehrrobert tertcorepromotormutationsinearlyonsetbladdercancer